Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $1.5 million.

  • Northwest Biotherapeutics' Shares Outstanding (Weighted Average) rose 1855.71% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 1855.71%. This contributed to the annual value of $1.2 million for FY2024, which is 1099.42% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) is $1.5 million, which was up 1855.71% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) ranged from a high of $1.5 million in Q3 2025 and a low of $834605.0 during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $1.1 million (2023), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) soared by 3032.76% in 2021, and later skyrocketed by 897.01% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $873517.0 in 2021, then increased by 16.29% to $1.0 million in 2022, then rose by 10.17% to $1.1 million in 2023, then rose by 10.99% to $1.2 million in 2024, then grew by 20.11% to $1.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $1.5 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.